Technical Analysis for CRTX - Cortexyme, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical CRTX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Calm After Storm | Range Contraction | 1.61% | |
Wide Bands | Range Expansion | 1.61% | |
Oversold Stochastic | Weakness | 1.61% | |
MACD Bearish Centerline Cross | Bearish | 3.27% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.27% | |
Calm After Storm | Range Contraction | 3.27% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
60 Minute Opening Range Breakout | about 18 hours ago | |
Up 3% | about 18 hours ago | |
Rose Above Previous Day's High | about 19 hours ago | |
Up 2% | about 19 hours ago | |
Up 1% | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Cortexyme is a clinical stage pharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's disease and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. The company's lead investigational medicine, COR388, is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in patients with mild to moderate Alzheimer’s.
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Inflammation Alzheimer's Disease Stage Pharmaceutical Degenerative Disease Mild Neurology Degenerative Diseases Neurodegeneration Nervous System
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Inflammation Alzheimer's Disease Stage Pharmaceutical Degenerative Disease Mild Neurology Degenerative Diseases Neurodegeneration Nervous System
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 58.99 |
52 Week Low | 26.66 |
Average Volume | 330,443 |
200-Day Moving Average | 43.82 |
50-Day Moving Average | 33.97 |
20-Day Moving Average | 39.27 |
10-Day Moving Average | 36.60 |
Average True Range | 4.02 |
ADX | 25.53 |
+DI | 23.13 |
-DI | 28.95 |
Chandelier Exit (Long, 3 ATRs ) | 40.75 |
Chandelier Exit (Short, 3 ATRs ) | 41.56 |
Upper Bollinger Band | 52.24 |
Lower Bollinger Band | 26.29 |
Percent B (%b) | 0.25 |
BandWidth | 66.10 |
MACD Line | -0.96 |
MACD Signal Line | 0.49 |
MACD Histogram | -1.4529 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 35.74 | ||||
Resistance 3 (R3) | 35.78 | 34.87 | 35.26 | ||
Resistance 2 (R2) | 34.87 | 34.14 | 34.85 | 35.10 | |
Resistance 1 (R1) | 33.87 | 33.69 | 34.37 | 33.83 | 34.94 |
Pivot Point | 32.96 | 32.96 | 33.21 | 32.94 | 32.96 |
Support 1 (S1) | 31.96 | 32.23 | 32.46 | 31.92 | 30.80 |
Support 2 (S2) | 31.05 | 31.78 | 31.03 | 30.64 | |
Support 3 (S3) | 30.05 | 31.05 | 30.48 | ||
Support 4 (S4) | 30.01 |